Drug intelligence / Profile preview

ILB-22X

Development stage: Unknown
Lead developer: ILIAS Biologics

Overview

ILB-22X is an investigational drug currently in the discovery phase of development by ILIAS Biologics, Inc. It is being explored for its potential in treating various conditions, including neoplasms, nervous system diseases, and specifically glioblastoma multiforme. The precise mechanism of action for ILB-22X has not been publicly disclosed.

Beyond the preview

Go deeper on ILB-22X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-22X.

Explore the full profile